Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2012 by National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: October 22, 2009
Last updated: November 16, 2012
Last verified: November 2012

RATIONALE: Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.

PURPOSE: This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma.

Condition Intervention
Lymphoproliferative Disorder
Other: biologic sample preservation procedure
Other: informational intervention

Study Type: Observational
Official Title: Rare And Cutaneous Non-Hodgkin Lymphoma Registry

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Clinical features, treatment, and outcomes [ Designated as safety issue: No ]
  • Pathologic and biologic features of these diseases, including molecular diagnostics and flow cytometry [ Designated as safety issue: No ]
  • Establishment of a bank of these pathologically reviewed diseases and make specimens of blood and tissue available to qualified researchers [ Designated as safety issue: No ]
  • Sub-groups of these diseases that could be targeted for future biologic, pathologic, or therapeutic studies [ Designated as safety issue: No ]

Study Start Date: May 2005
Detailed Description:


  • To determine the clinical features, treatment, and outcome of patients with rare or cutaneous pediatric non-Hodgkin lymphoma (NHL).
  • To determine the pathologic and biologic features of these diseases, including molecular diagnostics and flow cytometry.
  • To establish a bank of these pathologically reviewed diseases and make specimens of blood and tissue available to qualified researchers.
  • To determine sub-groups of these diseases that could be targeted for future biologic, pathologic, or therapeutic studies.

OUTLINE: On study data will include presenting symptoms and signs, physical description of the tumor if it is on the skin, results of metastatic evaluation, stage (if available), blood count, markers, and the results of viral serologies. Any existing underlying conditions that could predispose to lymphoma will also be noted.

Demographic and outcomes data will be stored and maintained by the COG Research Data Center. Demographic data will be linked to the specimen data in the BPC database.

The approach of this study is prospective data collection, including central pathologic review, relevant biologic studies, submission of material to the Biopathology Center (BPC) and collection of diagnostic and outcome data. Participants will be registered with a standard COG registration form for documentation of age, gender, race, date of diagnosis, initial presentation, initial work-up, and stage according to the standard staging for the specific disease, initial diagnostic procedure, and institutional diagnosis. Tissue will be sent according to guidelines in Section 4.0. Follow-up data, including relapse or progression and vital status will be reported annually for 5 years.

Patients will be followed annually for 5 years and data will be collected including vital status, evidence/absence of disease, type of treatment received, progression/relapse and whether the patient continues on study.


Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of non-Hodgkin lymphoma (NHL)

    • Any histology, except for Burkitt or Burkitt-like, diffuse large B-cell, anaplastic large cell, or lymphoblastic lymphoma
    • Primary CNS, primary cutaneous NHL, or lymphoproliferative diseases of any histology allowed
  • Pathological specimen from site not treated within the past 6 months
  • Must have specimens available


  • Not specified


  • See Disease Characteristics
  • At least 6 months since prior chemotherapy irradiation to study lesion
  • At least 2 weeks since prior steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01000753

  Show 108 Study Locations
Sponsors and Collaborators
Children's Oncology Group
Study Chair: Amanda M. Termuhlen, MD Nationwide Children's Hospital
  More Information

Additional Information:
No publications provided Identifier: NCT01000753     History of Changes
Other Study ID Numbers: CDR0000404164, COG-ANHL04B1
Study First Received: October 22, 2009
Last Updated: November 16, 2012
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
adult diffuse small cleaved cell lymphoma
adult diffuse mixed cell lymphoma
grade 1 follicular lymphoma
grade 2 follicular lymphoma
grade 3 follicular lymphoma
childhood immunoblastic large cell lymphoma
adult immunoblastic large cell lymphoma
mantle cell lymphoma
marginal zone lymphoma
small lymphocytic lymphoma
primary central nervous system non-Hodgkin lymphoma
cutaneous B-cell non-Hodgkin lymphoma
cutaneous T-cell non-Hodgkin lymphoma
lymphoproliferative disorder

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Lymphoma, Large-Cell, Immunoblastic
Neoplasms by Histologic Type
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on July 28, 2014